Market Place
Sourcing Support
CervoMed Announces Key Senior Leadership Appointments
13 Nov 2024 //
GLOBENEWSWIRE
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
08 Nov 2024 //
GLOBENEWSWIRE
CervoMed to Participate in Upcoming Investor Conferences
07 Nov 2024 //
GLOBENEWSWIRE
CervoMed Presents Key Takeaways from CTAD Alzheimer`s Conference
04 Nov 2024 //
GLOBENEWSWIRE
CervoMed to Present at 8th International Lewy Body Dementia Conf
29 Oct 2024 //
GLOBENEWSWIRE
CervoMed Announces Last Patient Visit In Phase 2b RewinD-LB Trial
15 Oct 2024 //
GLOBENEWSWIRE
CervoMed Joins 3rd Annual ROTH Healthcare Conference
02 Oct 2024 //
GLOBENEWSWIRE
CervoMed To Deliver Presentations At CTAD Conference
26 Sep 2024 //
GLOBENEWSWIRE
CervoMed to Participate in Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
CervoMed Featured in Fortune for Advances in Treatment of Dementia
22 Aug 2024 //
GLOBENEWSWIRE
CervoMed Reports Q2 2024 Results And Provides Corporate Updates
12 Aug 2024 //
GLOBENEWSWIRE
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
30 Jul 2024 //
GLOBENEWSWIRE
CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024
29 Jul 2024 //
GLOBENEWSWIRE
CervoMed to Participate in the Emerging Growth Conference
17 Jul 2024 //
GLOBENEWSWIRE
CervoMed To Host KOL Event On Neflamapimod For Lewy Body Dementia
11 Jul 2024 //
GLOBENEWSWIRE
CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
24 Jun 2024 //
GLOBENEWSWIRE
CervoMed Completion Pha 2b RewinD-LB Clinical Trial of Neflamapimod
11 Jun 2024 //
GLOBENEWSWIRE
CervoMed to Appoint William Elder as Chief Financial Officer
20 May 2024 //
GLOBENEWSWIRE
CervoMed Reports Q1 2024 Financials, Corporate Updates
15 May 2024 //
GLOBENEWSWIRE
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
CervoMed Announces Up to $149.4 Million Private Placement
28 Mar 2024 //
GLOBENEWSWIRE
CervoMed to Participate in Upcoming Investor Conferences
28 Mar 2024 //
GLOBENEWSWIRE
CervoMed Announces Presentation of Data from the AscenD-LB Phase 2a Trial
05 Mar 2024 //
GLOBENEWSWIRE
CervoMed to Participate in the BIO CEO and Investor Conference
21 Feb 2024 //
GLOBENEWSWIRE
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial
12 Feb 2024 //
GLOBENEWSWIRE
CervoMed Announces Appointment of Joshua Boger as Chair of the Board
07 Feb 2024 //
GLOBENEWSWIRE
CervoMed to Participate in the Emerging Growth Conference 67
05 Feb 2024 //
GLOBENEWSWIRE
CervoMed to Participate in the Emerging Growth Conference 66
05 Jan 2024 //
GLOBENEWSWIRE
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference
05 Oct 2023 //
PR NEWSWIRE
CervoMed Announces Completion of Merger with EIP Pharma
16 Aug 2023 //
PR NEWSWIRE
EIP Pharma Announces First Patient Dosed in Ph 2b Trial Evaluating Neflamapimod
14 Aug 2023 //
PR NEWSWIRE
EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference
03 Aug 2023 //
PR NEWSWIRE
EIP Pharma to Present at JMP Securities Life Sciences Conference
11 May 2023 //
PR NEWSWIRE
EIP Pharma and Diffusion Announce Merger Agreement to Create CNS-focused Company
30 Mar 2023 //
GLOBENEWSWIRE
EIP fuses with Diffusion to get ex-Vertex drug to dementia data
30 Mar 2023 //
FIERCE BIOTECH
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
16 Dec 2022 //
GLOBENEWSWIRE
Diffusion Pharma Sends Letter to Stockholders Highlighting Strength
05 Dec 2022 //
GLOBENEWSWIRE
Presentation of MRI data at Clinical Trials and Alzheimer`s Disease (CTAD)
02 Dec 2022 //
PRNEWSWIRE
Diffusion PharmaSees Significant Progress in its Strategic Review Process
14 Nov 2022 //
GLOBENEWSWIRE
Diffusion Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Diffusion Announces Process to Evaluate Alternatives to Better Leverage TSC
25 Oct 2022 //
GLOBENEWSWIRE
EIP Pharma Publishes Data of Preclinical and Phase 2a Results for Neflamapimod
21 Sep 2022 //
BUSINESSWIRE
Diffusion Pharmaceuticals Reports Q2 2022 Rusult and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
Diffusion Pharma to Initiate PII Trial in Patients with GBM
26 Jul 2022 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
23 Jun 2022 //
GLOBENEWSWIRE
Diffusion Pharma Appoints Raven Jaeger, M.S., as Chief Regulatory Officer
18 May 2022 //
GLOBENEWSWIRE
Diffusion Pharma to Present at H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
04 May 2022 //
GLOBENEWSWIRE
Diffusion Pharma Announces 1-for-50 Reverse Stock Split
18 Apr 2022 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
11 Apr 2022 //
GLOBENEWSWIRE
Diffusion Pharma Announces New Date for Special Meeting of Stockholders
08 Apr 2022 //
GLOBENEWSWIRE
Diffusion Pharma Reports 2021 Financial Results and Provides Business Update
21 Mar 2022 //
GLOBENEWSWIRE
Diffusion Pharma Expands its Scientific Advisory Board
24 Feb 2022 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect
20 Dec 2021 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
22 Nov 2021 //
BIOSPACE
EIP: neflamapimod has disease-modifying potential in dementia with Lewy Bodies
10 Nov 2021 //
PRNEWSWIRE
EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial
04 Nov 2021 //
PRNEWSWIRE
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners
28 Oct 2021 //
GLOBENEWSWIRE
Diffusion Pharmaceuticals Issues Letter to Shareholders
09 Sep 2021 //
GLOBENEWSWIRE
